Evidence map›Paper›PMID 30720000›Full record

ReviewSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

Hepatitis B care pathway in Saudi Arabia: Current situation, gaps and actions.

Abdulrahman A Aljumah, Mohamed Babatin, Almoataz Hashim, Faisal Abaalkhail, Nathalie Bassil, Mohamed Safwat, Faisal M Sanai

Abstract readReview
In one paragraph

Review in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Epidemiologic and clinical updates on viral infections in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Epidemiology of Hepatitis B in Saudi Arabia from 2006 to 2021.Hepatic medicine : evidence and research · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdulrahman A AljumahHepatology Division, Department of Hepatobiliary Sciences and Organ transplant Center, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
Mohamed BabatinGastroenterology Unit, Department of Medicine, King Fahad Hospital, Jeddah, Kingdom of Saudi Arabia.
Almoataz HashimGastroenterology Unit, Department of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.
Faisal AbaalkhailDivision of Organ Transplant Center, Department of Liver Transplantation and Hepatobiliary-Pancreatic Surgery, King Faisal Specialist Hospital and Research Center; Department of Medicine, College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia.
Nathalie BassilIQVIA, Dubai, United Arab Emirates.
Mohamed SafwatIQVIA, Dubai, United Arab Emirates.
Faisal M SanaiGastroenterology Unit, Department of Medicine, King Abdulaziz Medical City, Jeddah; Liver Disease Research Center, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection remains a public health problem worldwide. In this review, we aim to assess the current situation of the HBV care pathway in the Kingdom of Saudi Arabia (KSA), identify gaps/barriers therein, and recommend initiatives to be taken to improve the management of such patients. Towards this end, a literature search was conducted in PubMed and free Internet searches. Interviews with individuals and focus group discussions were held with HBV experts in KSA. Although significant improvements have been made in the past 30 years in KSA in terms of the decline in prevalence (currently estimated to be around 1.3%), the morbidity and mortality related to the disease have not shown a parallel decline. This makes HBV an important public health concern. Furthermore, poor disease awareness, low diagnosis rates, and nonadherence to therapy amplify the disease burden. There are several mandated national screening structures present; however, established protocols for those who test positive and subsequent linkage-to-care are inadequate. In the absence of a virologic cure, a concerted effort should be made to provide safe and effective lifelong treatment. This review provides recommendations to reduce the HBV disease burden in the Saudi population.

Indexed as

Drug MonitoringAwarenessCost of IllnessDiagnostic Screening ProgramsFemaleHepatitis BHepatitis B virusHumansImmunization ProgramsMaleMorbidityPrevalenceSaudi ArabiaAwarenessdiagnosisepidemiologyhepatitis BSaudi Arabiatreatment

Identifiers

PMID30720000
PMCPMC6457186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.